Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Albireo Pharma
Albireo Pharma
(ALBO)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Bylvay
Odevixibat
2021-07-16
2031-2041
Pruritus
,
Intrahepatic cholestasis
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Odevixibat
intrahepatic cholestasis
,
liver diseases
,
healthy volunteers/patients
,
biliary liver cirrhosis
,
liver cirrhosis
,
fibrosis
,
pruritus
,
cholestasis
,
alagille syndrome
,
syndrome
Bevifimod
macular edema
,
macular degeneration
,
choroidal neovascularization
,
refractive errors
,
myopia
,
astigmatism
,
hyperopia
,
contact lenses
,
hypertension
,
ocular hypertension
,
glaucoma
,
open-angle glaucoma
Elobixibat
non-alcoholic fatty liver disease
,
dyslipidemias
,
constipation
Insulin
hiv infections
,
hiv
,
type 1 diabetes mellitus
,
diabetes mellitus
,
type 2 diabetes mellitus
,
insulin resistance
,
inflammation
,
myocardial infarction
,
hyperglycemia
,
infarction
,
heart failure
,
rheumatoid arthritis
,
arthritis
,
hypoglycemia
Viaject
healthy volunteers/patients
,
renal insufficiency
,
critical illness
,
parkinson disease
,
cystic fibrosis
,
hyperglycemia
,
overweight
,
fibrosis
,
sepsis
,
pituitary dwarfism
,
dwarfism
,
cardiovascular diseases
,
asthma
,
body weight changes
,
leukemia
,
lymphoma
,
precursor cell lymphoblastic leukemia-lymphoma
,
lymphoid leukemia
,
chronic obstructive pulmonary disease
,
gestational diabetes
,
nutrition disorders
,
cardiac surgical procedures
,
septic shock
,
shock
,
toxemia
,
diabetes mellitus
,
type 2 diabetes mellitus
,
type 1 diabetes mellitus
,
hypoglycemia
,
drug delivery systems
,
insulin resistance
,
obesity
,
fatty liver
,
atherosclerosis
,
arteriosclerosis
,
inflammation
,
diabetic ketoacidosis
,
chronic renal insufficiency
,
respiratory insufficiency
,
surgical wound infection
,
latent autoimmune diabetes in adults
,
heart disease risk factors
,
hemostasis
,
patient participation
,
sedentary behavior
Isoxaflutole
healthy volunteers/patients
,
myelodysplastic syndromes
,
myeloproliferative disorders
,
biphenotypic leukemia acute
,
myelodysplastic-myeloproliferative diseases
,
myeloid leukemia acute
,
monocytic leukemia acute
,
non-hodgkin lymphoma
,
large b-cell lymphoma diffuse
,
b-cell lymphoma
,
burkitt lymphoma
,
macular edema
,
parkinson disease
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use